Notwithstanding several setbacks, quite a few MDM2 inhibitors have now progressed into late-stage clinical progress. New tactics have also been developed to enhance the efficacy of MDM2 inhibitors also to mitigate their on-concentrate on toxicity. In this particular overview, we summarize the development and worries in the event of a MDM2 targeted